Medical Condition News

RSS

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis®

2 Jun 2015

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

Northwest Biotherapeutics, a U.S. biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, over the weekend in Chicago released promising new data on their Phase I trial of DCVax-Direct for direct injection into all types of inoperable solid tumors.

2 Jun 2015

New article on occupations most likely to cause mesothelioma

Mesothelioma.us, a website that is devoted to offering people helpful resources and information about mesothelioma, has just posted a new article that takes a look at which occupations are most likely to cause mesothelioma. Titled "Asbestos Jobs Causing Mesothelioma," the article explains how working directly with asbestos is the most common way to develop the serious health condition, which attacks the lining of the lungs, stomach or heart.

2 Jun 2015

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

Stempeutics Research, a group company of Manipal Education & Medical Group and a joint venture with Cipla Group, announced today that the European Medicines Agency (EMA) has granted Orphan Drug Designation for its drug Stempeucel® for the treatment of Thromboangiitis Obliterans.

2 Jun 2015

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

AstraZeneca and MedImmune, the company’s global biologics research and development arm, today presented encouraging results from their novel combination-focused immuno-oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2015.

2 Jun 2015

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

Despite surgical advances, pancreatic cancer continues to be one of the most deadly and difficult cancers to manage due to a lack of effective therapies. However, VCU Massey Cancer Center and VCU Institute of Molecular Medicine (VIMM) scientists in the lab of Paul B. Fisher, M.Ph., Ph.D., are hoping to change that with a novel combination of an experimental drug and a common antibiotic that has shown promising results in preclinical experiments.

2 Jun 2015

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

DNA Therapeutics, a private biopharmaceutical company developing DT01, a first-in-class clinical pan DNA repair inhibitor to treat tumors resistant to conventional treatments, will today present the results of the first-in-man phase 1/2a trial of DT01 in combination with radiation therapy in patients with cutaneous metastatic melanoma.

2 Jun 2015

Ariana Pharma joins the GastricGlycoExplorer consortium

This collaboration is carried out within the GastricGlycoExplorer consortium, a European Commission funded project. The consortium aims at discovering and developing new diagnostic signatures by characterizing the sugars that are attached to the surface of gastric tissue. "Glycomics" provides a systematic approach for studying sugars that are naturally present on cell surfaces and its application may lead to determine early markers of gastric cancer.

2 Jun 2015

Intermountain Precision Genomics: Precision medicine can benefit advanced cancer patients without increasing costs

Two new studies conducted by Intermountain Healthcare’s Intermountain Precision Genomics reveal that precision medicine can improve survival in advanced cancer patients – and do so without increasing costs.

2 Jun 2015

ESMO-MCBS tool will help oncology clinicians evaluate most effective anti-cancer medicines

ESMO announced the publication of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients.

2 Jun 2015

$Matched therapy and FoundationOne genomic profiling improve outcomes in patients with refractory cancer$

Matched therapy and FoundationOne genomic profiling improve outcomes in patients with refractory cancer

Foundation Medicine, Inc. and collaborators from the University of Texas MD Anderson Cancer Center and Sarah Cannon Research Institute at HealthOne today announced compelling new data demonstrating that matching patients to targeted therapies based on the unique molecular profile of the patient’s advanced cancer leads to improved outcomes across a variety of key measures, including overall survival.

2 Jun 2015

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

A large cooperative-group study directed by the Alliance for Clinical Trials in Oncology has confirmed previous evidence that the drug lenalidomide delays time to disease progression for patients with multiple myeloma and is an important treatment option for patients with this rare but increasingly common cancer of the blood and marrow.

2 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

Boehringer Ingelheim today announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib, in patients with advanced squamous cell carcinoma (SCC) of the lung, progressing after treatment with first-line chemotherapy.

2 Jun 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

AstraZeneca today announced preliminary efficacy and safety data for AZD9291 in the first-line treatment of epidermal growth factor receptor mutation positive (EGFRm) advanced non-small cell lung cancer (NSCLC).

2 Jun 2015

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

AbbVie, a global biopharmaceutical company, today announced findings from a Phase 2 study of the investigational medicine veliparib combined with the chemotherapy regimen carboplatin and paclitaxel that showed an improvement in median progression-free survival (PFS) in patients with previously untreated metastatic or advanced non-small cell lung cancer (NSCLC) who are current smokers.

2 Jun 2015

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Foundation Medicine, Inc. today presented new data including promising clinical outcomes underscoring the importance of integrating comprehensive genomic profiling with FoundationOne® into clinical oncology care for the treatment of biliary tract cancers.

2 Jun 2015

Helsinn's Akynzeo for CINV prevention receives EC approval

Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.

2 Jun 2015

Genetically-programmed probiotics could help detect liver cancer metastases early-on

Scientists at the University of California, San Diego and the Massachusetts Institute of Technology have described a new method for detecting liver cancer metastases in mice. The approach uses over-the-counter probiotics genetically programmed to produce signals easily detectable in urine when liver cancer metastases are present.

2 Jun 2015

NSCLC treatment market forecast to reach $7.9 billion by 2020

The Non-Small Cell Lung Cancer treatment market will be driven primarily by the introduction of numerous premium therapies, particularly in second-line and squamous cell treatment settings, which either replace or combine with generic chemotherapies.

2 Jun 2015

Medical Condition News

ASCO 2015: AMGEN presents new data evaluating less-frequent dosing of kyprolis for multiple myeloma patients

NW Bio releases promising new data on DCVax-Direct Phase I trial for inoperable solid tumors

New article on occupations most likely to cause mesothelioma

EMA grants Orphan Drug Designation to Stempeucel for treatment of Thromboangiitis Obliterans

MedImmune, AstraZeneca present encouraging results from new combination-focused immuno-oncology portfolio at ASCO 2015

Experimental drug and common antibiotic combination holds promise for pancreatic cancer treatment

DNA Therapeutics to present DT01 phase 1/2a trial results at ASCO 2015

Ariana Pharma joins the GastricGlycoExplorer consortium

Intermountain Precision Genomics: Precision medicine can benefit advanced cancer patients without increasing costs

ESMO-MCBS tool will help oncology clinicians evaluate most effective anti-cancer medicines

Matched therapy and FoundationOne genomic profiling improve outcomes in patients with refractory cancer

Maintenance therapy with lenalidomide benefits patients with multiple myeloma

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Boehringer Ingelheim presents afatinib LUX-Lung 8 trial data at ASCO 2015

AstraZeneca announces efficacy and safety data for AZD9291 in first-line treatment of EGFRm advanced NSCLC

Phase 2 results from Abbvie’s veliparib study in NSCLC presented at ASCO 2015

New data underscores the importance of FoundationOne genomic profiling for treatment of biliary tract cancers

Helsinn's Akynzeo for CINV prevention receives EC approval

Genetically-programmed probiotics could help detect liver cancer metastases early-on

NSCLC treatment market forecast to reach $7.9 billion by 2020

Advancing brain microphysiological systems (bMPS)

PhD researcher at LifeArc

Unveiling Hidden Potential: Organoids for Disease Modeling in Neuroscience Research

Latest News